Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults

Novavax announced recently of top-line results of its Phase 2 clinical trial of NanoFlu. The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax’ Matrix-M adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older. As Novavax previously announced, the U.S. Food and Drug Administration acknowledged that the accelerated approval pathway may be available for NanoFlu